Creative Biomart Blog

Thu, 2019/01/31

New Study Published on J Virol Reveals The Molecular Mechanism of Human T Cell Leukemia Virus Infection and Spread

Recently, research published in the Journal of Virology, scientists from the University of Minnesota developed a new strategy that is expected to block the spread of a highly infectious virus in remote areas of central Australia. Human T-cell leukemia virus type 1 (HTLV-1) infected more than 40% adults in the community, as the first human-type cancer virus discovered by scientists, HTLV-1 induces leukemia and lymphoma. “Currently, we have clarified how HTLV-1 produces viral particles to spread to other cells in the body.” said researcher Dr. Louis Mansky, “In this study, we made mutatio

Fri, 2019/01/18

The Essence of Science Journal in December 2018

1.Science: Pro-Linked Protein 2 Cutting Can Prevent Heart Failure doi:10.1126/science.aan3303; doi:10.1126/science.aav8956 Dr. Long-Sheng Song, a researcher at the University of Iowa in the United States, and his team have confirmed in a previous study that a structural protein called junctophilin-2 (JP2) is essential for the heartbeat. Heart failure is associated with this protein loss or destruction. Now, in a new study, researchers from the University of Iowa, Shanghai Jiaotong University, and Nantong University focus on JP2. They used mice as a research object, revealing that unde

Mon, 2019/01/14

J Cell Biol: How Does a Genetic Mutation Induce a Neurological Disease Such as Parkinson's?

Mutations in multiple genes are directly related to Parkinson's disease, but researchers are not sure how these mutations affect individuals with Parkinson's disease. A recent study published in The Journal of Cell Biology, in the study, scientists from Yale University focused on a genetic mutation that induced familial Parkinson's disease. They found that the gene encodes a specific protein that controls lipids transfer between organelle membranes. In the article, the researchers investigated the key role of VPS13 protein, and the dysfunction of VPS13 protein plays an important role in

Sat, 2019/01/12

Embo Mol Med: Identification of a Novel Therapeutic Target for the Chronic Inflammatory Colon Cancer

Recently, a research report published in the international magazine EMBO Molecular Medicine, scientists from the Barcelona Institute of Biomedical Research discovered a new mechanism that can promote inflammation-related colon cancer, and the mechanism also can help develop new cancer therapies as a new target. More than 1 million people worldwide are diagnosed with colon cancer each year. Although many cases are spontaneous, chronic inflammation is also a major cause of colon cancer. Researcher Angel R. Nebreda said that the capability of myeloid cells enhance tumorigenesis may be determin

Thu, 2019/01/10

What’s the Future of Biosimilar Drugs Development?

In general, biosimilars are generic products of biopharmaceuticals. Different from generics, they are “similar” and therefore require approval procedures similar to new branded drugs. Although there are about 25 approved biosimilars in Europe, they did not receive the same treatment in the United States. Despite 11 drugs are approved in the United States, only about 3 kinds can be utilized in patients for branded pharmaceutical companies are using commercial strategies to prevent biosimilar drugs from competing for their current high-priced biopharmaceuticals. The US FDA launched a biosi

Wed, 2019/01/09

Dna2 Deficiency May Result in DNA Insertions at Chromosomal Breaks

Cells have many mechanisms to protect genomic integrity, including the process of repairing errors that may occur during DNA replication. The Dna2 nuclease is involved in DNA repair, but little is known about its effect on chromosomal instability. In a new study, researchers from several research institutions, including Baylor College of Medicine, revealed that when Dna2 is missing, smaller DNA fragments jump from the entire genome to the chromosomal breaks. This new mechanism may explain similar events that are often observed during cancer or antibody diversification. The study was published

Wed, 2018/12/05

JCI: STAT3 Inhibitor May Provide New Hope for Leukemia Treatment

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are malignant hematopoietic stem cell disorders, and abnormal stem cell populations in hematopoietic stem and progenitor cells can cause disease. Traditional treatments to date can not completely eliminate these abnormal hematopoietic stem cells associated with the disease. Recently, researchers from the Albert Einstein College of Medicine have discovered a prognosis molecule that predicts both MDS and AML. Furthermore, an antisense oligonucleotide targeting the disease-causing molecule was identified to have a potential therap

Tue, 2018/12/04

New Drug Targets That Are Expected to Treat Malignant Cancer Discovered

Recently, scientists from the Dana-Farber Cancer Institute have discovered new drug targets for two malignant cancers. It is expected to develop new therapies for the treatment of synovial sarcoma and malignant rods-shaped tumors. Related research result was published in the Nature Cell Biology. The researchers say that these two cancers depend on a new molecular called ncBAF, which plays a key role in regulating gene activity, consisting of multiple specific protein subunits. Biologically or chemically inactivating components of ncBAF may specifically impair proliferation of synovial sarco